ADvantage Therapeutics

ADvantage Therapeutics is developing therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company’s lead compound, AD04™, is an injectable treatment currently undergoing a confirmatory Phase 2b clinical trial in Europe to evaluate its safety and efficacy in early Alzheimer's disease.